
Assessing breast MRI scans, pathology and clinical data, the AI-powered TumorSight Risk software reportedly provides five- and 10-year risk for breast cancer recurrence for women with HR+, HER2-negative stage I-IIIA breast cancer.
Keith J. Dreyer, DO, has created and provided this interactive guide to help radiologists determine the best way to participate in the meaningful use program.
Do you qualify for the federal meaningful use program? Keith J. Dreyer, DO, FACR, FSIIM, a leading authority on meaningful use in radiology, developed a short survey to guide eligibility and participation.
The survey is also available at






